A Phase II Study of Multiple Dosing Regimens of Intravaginally Administered 851B

Sponsor

3M Pharmaceuticals

Principal Investigator

Dr. Paola Gehrig, Obstetrics and Gynecology

Project Run Dates

3/24/2006 to 6/1/2009

Total Award Amount

$55,965.27

 

Summary

The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.

 

Associated Publications and other materials

Study Record Detail on Clinical Trials.gov

Associated Award Numbers: A06-1223-002, A06-1223-003, A06-1223-004, A06-1223-005, A06-1223-006, A06-1223-007, A06-1223-008, A06-1223-009, A06-1223-010, A06-1223-011, A06-1223-012, A06-1223-013, A06-1223-014, A06-1223-015, A06-1223-016